Medicina molecular en anestesia
Barra lateral del artículo
Contenido principal del artículo
Resumen
El futuro de la anestesia apunta a la implementación de la biología molecular entre sus disciplinas a fin de generar terapias personalizadas. El análisis de los genes permite contar con un elemento más a la hora de decidir sobre administración de fármacos, búsqueda de mecanismos de dolor, prueba de técnicas y desarrollo de nuevos agentes anestésicos para garantizar la eficacia de tratamientos o procedimientos
Downloads
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
Powe DG, Keightley A, Chester M, et al. Mucosal thickening in allergic and idiopathic rhinitis mucosa and its probable mechanism. Ann Allergy Asthma Immunol. 2009;103(1):14-9. DOI: https://doi.org/10.1016/S1081-1206(10)60137-8
Mashour GA, Forman SA, Campagna JA. Mechanisms of general anesthesia: from molecules to mind. Best Pract Res Clin Anaesthesiol. 2005;19(3):349-64. DOI: https://doi.org/10.1016/j.bpa.2005.01.004
Baer-Dubowska W, Majchrzak-Celińska A, Cichocki M. Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacol Rep. 2011;63(2):293-304. DOI: https://doi.org/10.1016/S1734-1140(11)70498-4
Ruggieri VL, Arberas CL. [Genetic syndromes recognizable in the neonatal period]. Medicina (B Aires). 2009;69(1 Pt 1):15-35.
Shah RR, Shah DR. Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol. 2012;74(4):698-721. DOI: https://doi.org/10.1111/j.1365-2125.2012.04328.x
Wislocki PG, Miwa GT, Lu AY. Reactions catalyzed by the cytochrome P-450 system. En: Jacobi WB, ed. Vol. 1. Enzymatic basis of detoxication. New York: Academic Press; 1980. p. 135-82 DOI: https://doi.org/10.1016/B978-0-12-380001-5.50013-X
Nebert DW, Gonzalez FJ. P450 genes: structure, evolution, and regulation. Annu Rev Biochem. 1987;56:945-93. DOI: https://doi.org/10.1146/annurev.bi.56.070187.004501
Guengerich FP. Reactions and significance of cytochrome P-450 enzymes. J Biol Chem. 1991;266(16):10019-22. DOI: https://doi.org/10.1016/S0021-9258(18)99177-5
Porter TD, Coon MJ. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem. 1991;266(21):13469-72 DOI: https://doi.org/10.1016/S0021-9258(18)92717-1
Ortiz de Montellano PR, editor. Cytochrome P450: structure, mechanism, and biochemistry. 2nd ed. New York: Plenum Press; 1995. DOI: https://doi.org/10.1007/978-1-4757-2391-5
Derijks LJ, Gilissen LP, Hooymans PM, et al. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(5):715-29. DOI: https://doi.org/10.1111/j.1365-2036.2006.02980.x
Lennard L, Lilleyman JS, Van Loon J, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336(8709):225-9. DOI: https://doi.org/10.1016/0140-6736(90)91745-V
Hollander AA, van Saase JL, Kootte AM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet. 1995;345(8950):610-4 DOI: https://doi.org/10.1016/S0140-6736(95)90520-0
Milano G, Etienne MC, Pierrefite V, et al. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer. 1999;79(3-4):627-30. DOI: https://doi.org/10.1038/sj.bjc.6690098
Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 1993;53(22):5433-8.
Uetake H, Ichikawa W, Takechi T, et al. Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res. 1999;5(10):2836-9.
Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43(1):99-102. DOI: https://doi.org/10.1086/504874
Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23(10):1603-14. DOI: https://doi.org/10.1016/S0149-2918(01)80132-6
Cutrell AG, Hernandez JE, Fleming JW, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38(12):2171-2. DOI: https://doi.org/10.1345/aph.1E202
Descalzi G, Ikegami D, Ushijima T, et al. Epigenetic mechanisms of chronic pain. Trends Neurosci. 2015;38(4):237-46.Erratum in: Trends Neurosci. 2015;38(9):579. DOI: https://doi.org/10.1016/j.tins.2015.02.001
Fernandez Robles CR, Degnan M, Candiotti KA. Pain and genetics. Curr Opin Anaesthesiol. 2012;25(4):444-9. DOI: https://doi.org/10.1097/ACO.0b013e3283556228
Seo S, Grzenda A, Lomberk G, et al. Epigenetics: a promising paradigm for better understanding and managing pain. J Pain. 2013;14(6):549-57. DOI: https://doi.org/10.1016/j.jpain.2013.01.772
Chen YC, Auer-Grumbach M, Matsukawa S, et al. Transcriptional regulator PRDM12 is essential for human pain perception. Nat Genet. 2015;47(7):803-8. Erratum in: Nat Genet. 2015;47(8):962.
Klepstad P, Rakvåg TT, Kaasa S, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48(10):1232-9 DOI: https://doi.org/10.1111/j.1399-6576.2004.00517.x
Rakvåg TT, Ross JR, Sato H, et al. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements incancer patients with pain. Mol Pain. 2008;4:64 DOI: https://doi.org/10.1186/1744-8069-4-64
Flanagan N, Healy E, Ray A, et al. Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation. Hum Mol Genet. 2000;9(17):2531-7. DOI: https://doi.org/10.1093/hmg/9.17.2531
Mogil JS, Ritchie J, Smith SB, et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet. 2005;42(7):583-7. DOI: https://doi.org/10.1136/jmg.2004.027698
Fernández Daza PL, Esquinca Cruz MT, Rodríguez MV, Valdespin Pérez R. Porfirias: consideraciones anestésicas. An Med (Mex). 2007;52(3):130-42.
McColl K, Dover S, Fitzsimons E, et al. Porphyrin metabolism and the porphyrias. En: Wheatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine. Oxford: Oxford University Press; 1996. p. 1388-99.
Stoelting RK, Dierdirf SF. Inborn errors of metabolism: anesthesia and co-existing disease. Hines RL, Marschall k. Stoelting’s anesthesia and co-existing disease. 4th ed. Philadelphia, PA: Churchill Livingstone, 2002. p. 455-60.
Baker SD, Taylor B. Anaesthesia is also risky in patients with porphyria. BMJ. 2000;321(7267):1023. DOI: https://doi.org/10.1136/bmj.321.7267.1023
Palmieri C, Vigushin DM, Peters TJ. Managing malignant disease in patients with porphyria. QJM. 2004;97(3):115-26. DOI: https://doi.org/10.1093/qjmed/hch027
Winkler AS, Peters TJ, Marsden JT, et al. Erythropoietin treatment in the neuropsychiatric porphyrias. Clin Chim Acta. 2003;338(1-2):61-6. DOI: https://doi.org/10.1016/j.cccn.2003.07.015
Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol. 2006;135(3):281-92. DOI: https://doi.org/10.1111/j.1365-2141.2006.06289.x
Hunter GH. Anesthetic considerations in hepatic porphyrias. CRNA. 1999;10(1):6-14.
Hahn M, Bonkovsky HL. Multiple chemical sensitivity syndrome and porphyria. A note of caution and concern. Arch Intern Med. 1997;157(3):281-5. DOI: https://doi.org/10.1001/archinte.1997.00440240039006
Sheppard L, Dorman T. Anesthesia in a child with homozygous porphobilinogen deaminase deficiency: a severe form of acute intermittent porphyria. Paediatr Anaesth. 2005;15(5):426-8. DOI: https://doi.org/10.1111/j.1460-9592.2005.01451.x